Zobrazeno 1 - 10
of 9 427
pro vyhledávání: '"drug conjugate"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 4, Pp 272-282 (2024)
An increasing number of newer targeted oncologic therapies approved for clinical use can cause drug-related pneumonitis. Drug-related pneumonitis can be difficult to diagnose and requires a high index of suspicion. This review serves as an update to
Externí odkaz:
https://doaj.org/article/675860ebbb4a4d6e852f7eea397ff0ce
Autor:
Leilei Qin, Ning Hu, Yanhao Zhang, Jianye Yang, Liqun Zhao, Xiaokai Zhang, Yun Yang, Jinyong Zhang, Yinshuang Zou, Keyu Wei, Chen Zhao, Yujian Li, Hao Zeng, Wei Huang, Quanming Zou
Publikováno v:
Journal of Advanced Research, Vol 65, Iss , Pp 239-255 (2024)
Introduction: Treating orthopedic implant-associated infections, especially those caused by Staphylococcus aureus (S. aureus), remains a significant challenge. S. aureus has the ability to invade host cells, enabling it to evade both antibiotics and
Externí odkaz:
https://doaj.org/article/352fc8c80b2b4593881169fe02968693
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6314-6342 (2024)
Antibody–drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment arma
Externí odkaz:
https://doaj.org/article/047bcb77f50d4fc083be6e1cddd8c98b
Autor:
Lai Wang, Haoyuan Yin, Jiao Jiang, Qilin Li, Changxing Gao, Wenrui Li, Bo Zhang, Yue Xin, Hongyang Li, Ming Zhao, Qianjin Lu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 10, Pp 4560-4576 (2024)
Tripterygium wilfordii Hook F (TWHF) is a traditional Chinese medicine widely used in the treatment of systemic lupus erythematosus (SLE), with triptolide (TP) as its main active ingredient. However, its side effects also induced by TP, especially he
Externí odkaz:
https://doaj.org/article/1de8887387b14b4e86e1b223f6513efb
Publikováno v:
Trends in Pharmaceutical Sciences, Vol 10, Iss 3, Pp 205-214 (2024)
Immunotherapy is an emerging field in medicine using the body's immune to combat various diseases, particularly cancer. In recent years, several immunotherapy agents have obtained regulatory approval from the European Medicines Agency (EMA) and the U
Externí odkaz:
https://doaj.org/article/1b5a2d22ba6040c3b3757cc6437529ce
Autor:
Jiacheng Liu, Yaowei Bai, Xiaoming Liu, Binqian Zhou, Peng Sun, Yingliang Wang, Shuguang Ju, Chen Zhou, Chaoyang Wang, Wei Yao, Huihui Yang, Xin Jiang, Lian Yang, Dongyuan Wang, Chuansheng Zheng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract This study aimed to design a VEGFR-targeting peptide–drug conjugate with the ability to decrease tumor burden and suppress tumor angiogenesis, and to further evaluate the therapeutic effect of anti-PD-1 antibody in HCC therapy. A VEGFR-tar
Externí odkaz:
https://doaj.org/article/d2fe7673ef964b47901301c4080d2b6d
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Although antibody–drug conjugate (ADC) or immune checkpoint inhibitors (ICIs) alone fosters hope for the treatment of cancer, the effect of single drug treatment is limited and the safety profile of ADC and ICI therapy remains unclear. Thi
Externí odkaz:
https://doaj.org/article/a64ab320675c4741b82b8690439db206
Autor:
Mita Manna, Michelle Brabant, Rowen Greene, Michael Dean Chamberlain, Aalok Kumar, Nimira Alimohamed, Christine Brezden-Masley
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5694-5708 (2024)
Sacituzumab Govitecan (SG) is an antibody-drug conjugate (ADC) comprised of an anti-Trop-2 IgG1 molecule conjugated to SN-38, the active metabolite of irinotecan, via a pH-sensitive hydrolysable linker. As a result of recent Canadian funding for SG i
Externí odkaz:
https://doaj.org/article/7a6dcf3b67f148be83e018770a5a46ad
Autor:
Mattia Alberto Di Civita, Andrea Torchia, Daniele Santini, Daniele Marinelli, Virginia Magro, Marianna Cerro, Laura Pappalardo, Giulia Maltese, Fiorenza Santamaria, Luca Zacco, Dorelsa Buccilli, Ailin Dehghanpour, Iolanda Speranza, Alessandro Sciarra, Valeria Panebianco, Michela Roberto
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4713-4727 (2024)
Introduction. Platinum-based chemotherapy represents the standard of care (SoC) for the first-line treatment of advanced urothelial carcinoma (mUC). The benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy was recently
Externí odkaz:
https://doaj.org/article/9b78cad03c694aaaa786dc77973e882a
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-17 (2024)
Abstract Human trophoblastic cell surface antigen 2 (Trop2) is a glycoprotein, a cellular marker of trophoblastic and stem cells, and a calcium signaling transducer involved in several signaling pathways, leading to the proliferation, invasion, and m
Externí odkaz:
https://doaj.org/article/7214982032d74db3801c36504f675c87